via Tokyo University of Science
Scientists modified “mesenchymal stem cells” to carry anti-cancer drugs and deliver them to target cancers
Targeting drugs to cancer tissues is a major challenge in cancer treatment. Mesenchymal stem cells (MSCs) are known for their ability to find and target tumor cells in the body, but using MSCs for drug delivery has been tricky, because upon loading with drugs, MSCs lose their viability and migratory ability. Now, researchers from Tokyo University of Science have successfully modified MSCs to deliver large quantities of anti-cancer drugs in a targeted manner to developing cancer cells.
As humans evolve, cancer also evolves in parallel, making the race for finding efficient treatment methods for cancer patients challenging and constant. In addition to designing drugs for treatment, the delivery of these drugs to targeted organs is also a major challenge faced by the cancer research community.
Many research groups have tried to develop techniques to efficiently deliver anti-cancer drugs to tumors. An interesting way utilizes a distinct group of cells in our body, the mesenchymal stem cells (MSCs), which have a special ability to find and move towards tumors. This means that theoretically, we can load these “tumor-homing” MSCs with anti-cancer drugs and use them to hinder cancer progression. However, pilot studies show that the anti-cancer drug loading capacity of MSCs is limited, and they tend to lose their ability to target and reach tumor cells upon drug loading.
In a recent study published in Journal of Controlled Release, researchers from Japan, led by Dr. Kosuke Kusamori and Professor Makiya Nishikawa from Tokyo University of Science, sought to find out how to modify MSCs to bypass these problems. Dr. Kusamori, Assistant Professor in the University’s Department of Pharmacy says, “We wondered if the answer to our dilemma of modifying mesenchymal stem cells with an anticancer drug was to exploit the property of mesenchymal stem cells to accumulate in tumor tissues.”
Using the well-known “avidin-biotin complex” (ABC) method, the researchers used liposomes-cellular lipid bags popularly used as drug delivery systems-to carry the anti-cancer drug doxorubicin (DOX) to the surface of specific mouse MSCs. They named these lipid bags carrying DOX “DOX-Lips.”
The researchers found that the MSCs loaded with DOX-Lips could carry and selectively target mouse colon cancer cells growing in artificial cultures in the lab. These modified MSCs could not only carry a significant amount of the drug, but also efficiently deliver it inside the target cancer cells. To test if this feature is replicated in a living system, they used a mouse model with skin and lung cancer. They found that in both cases, DOX-Lips were able to efficiently reach cancer cells and release the drug into the cytoplasm of the cancer cells. The researchers concluded that the modified MSCs could completely suppress tumor growth in mouse models.
There are several advantages to this new method. First, the process is relatively faster than previously known methods. As Yukiya Takayama, a doctoral student in Professor Nishikawa’s lab and a co-author of the study observes, “The relatively short duration of the ABC method made it possible to quickly modify the cell surface with DOX-Lips and avoid cell damage.”
Second, this method did not affect the process of cell attachment to cancer cells, thereby ensuring maximum efficiency in drug delivery. Third, contrary to previous observations that lipid bags of only a certain size can be used to deliver drugs, this new study suggests that the size of the lipid bags very likely does not affect drug delivery; this finding can be exploited to deliver many different doses of drugs as well.
The combination of the ABC method and the use of Lips thus seems to be the answer to the researchers’ dilemma. Professor Nishikawa is excited about these results. “We have succeeded in developing a new targeted cancer therapy,” he observes. “Mesenchymal stem cells can migrate to brain tumors and minute cancer lesions that are otherwise inaccessible to conventional drug delivery systems. Our method may thus be effective against intractable cancers,” Nishikawa says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Modified stem cells
- CRISPR technology to cure sickle cell diseaseon January 20, 2021 at 4:00 pm
A new article reports two patients appear to have been cured of beta thalassemia and sickle cell disease after their own genes were edited with CRISPR-Cas9 technology. The two researchers who invented ...
- ASH 2020: The Next Waveon January 19, 2021 at 4:00 pm
Experts discussed "transformative" treatments and advanced genetic tracing in blood cancer at the 2020 American Society of Hematology Annual Meeting.
- Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitroon January 18, 2021 at 9:33 am
A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.
- New gene therapy methods deliver promiseon January 14, 2021 at 11:24 am
Two unpublished studies detail improved methods for delivering gene therapies to the brain: One involves a type of stem cell that can produce gene-altering proteins on-site; the other taps an ...
- Centre of Excellence in Stem Cell Metabolismon January 7, 2021 at 4:00 pm
nutrient sensing and mitochondrial biology to address how stem cell function can be modified through regulation of their metabolism. Our aim is to target tissue repair with metabolic tools, and to ...
Go deeper with Google Headlines on:
Modified stem cells
Go deeper with Bing News on:
Mesenchymal stem cells
- EV Biologics Has Engaged Foley & Lardner LLP for Legal Counsel in Intellectual Propertyon January 26, 2021 at 5:38 am
CHEYENNE, WY / ACCESSWIRE / January 26, 2021 / EV Biologics Corp, OTC: YECO today announced that it has entered into an engagement agreement with the esteemed international law firm, Foley & Lardner ...
- EV Biologics Corporation: EV Biologics Has Engaged Foley & Lardner LLP for Legal Counsel in Intellectual Propertyon January 26, 2021 at 5:23 am
YECO today announced that it has entered into an engagement agreement with the esteemed international law firm, Foley & Lardner LLP ...
- Tumor cells reveal a core syncytial drive to evade host defenseson January 25, 2021 at 5:21 am
Toxins, radiation, and normal metabolic processes together generate molecular lesions in every one of our cells to the tune of 10,000 to 1,000,000 hits per day. Fortunately, most of these code faults ...
- Oncotarget: Drug-resistant cells grow exponentially in metastatic prostate canceron January 25, 2021 at 4:03 am
The Oncotarget authors show that the drug-resistant, metastasis-causing cells are capable of producing drug-resistant, exponentially growing tumors, responsible for tumor growth as a patient receives ...
- The Global Stem Cell Market Estimated to Reach $16782.2 Million in Revenue by 2028on January 22, 2021 at 4:21 am
According to Triton s report the global stem cell market which garnered 9382 million in 2020 is predicted to advance at 7 54 of CAGR by 2028 A recent study by Triton Market Research titled Global Stem ...